The Fibromyalgia (Fibromyalgia Syndrome) drugs in development market research report provides comprehensive information on the therapeutics under development for Fibromyalgia (Fibromyalgia Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Fibromyalgia (Fibromyalgia Syndrome). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Fibromyalgia (Fibromyalgia Syndrome) and features dormant and discontinued products.
GlobalData tracks 20 drugs in development for Fibromyalgia (Fibromyalgia Syndrome) by 17 companies/universities/institutes. The top development phase for Fibromyalgia (Fibromyalgia Syndrome) is phase i with nine drugs in that stage. The Fibromyalgia (Fibromyalgia Syndrome) pipeline has 19 drugs in development by companies and one by universities/ institutes. Some of the companies in the Fibromyalgia (Fibromyalgia Syndrome) pipeline products market are: Luye Pharma Group, Shanghai Leado Pharmaceutical Technology and Tryptamine Therapeutics.
The key targets in the Fibromyalgia (Fibromyalgia Syndrome) pipeline products market include 5-Hydroxytryptamine Receptor 2A, Sodium Dependent Noradrenaline Transporter, and Sodium Dependent Serotonin Transporter.
The key mechanisms of action in the Fibromyalgia (Fibromyalgia Syndrome) pipeline product include 5-Hydroxytryptamine Receptor 2A Agonist with three drugs in Phase II. The Fibromyalgia (Fibromyalgia Syndrome) pipeline products include six routes of administration with the top ROA being Oral and four key molecule types in the Fibromyalgia (Fibromyalgia Syndrome) pipeline products market including Small Molecule, and Monoclonal Antibody.
Fibromyalgia (Fibromyalgia Syndrome) overview
Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis, or lupus. Treatment includes pain relievers, antidepressants, and anti-seizure drugs.
For a complete picture of Fibromyalgia (Fibromyalgia Syndrome)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
